51 reports

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022 Chapter ## Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Methodology Geographic Breakdown Analyst’s Credentials Related BCC Research Reports Chapter ## Summary and Highlights Market Con

  • Cancer
  • Ovarian Cancer
  • Therapy
  • World
  • Market Size

Note: ##.

  • Ovarian Cancer
  • World
  • Forecast
  • bioMerieux S.A.
  • Cepheid

Rucaparib is a top-of-the-line pharmaceutical preparation for the repair polymerase of DNA polymerase-## (PARP-##) poly-ADP.

  • Ovarian Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • China
  • Demand
  • Market Size
  • Biosino Bio-Technology & Science Inc

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

APPENDIX ##: TABULATED DATA ##. ##.

  • Clinical Trial
  • Ovarian Cancer
  • United States
  • Forecast
  • Nektar Therapeutics
  • Dormant Products, H1 2018
  • Dormant Projects, H1 2017

The ODAC reviewed findings from one Phase III clinical study and one Phase II study.

  • Hospital
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Novartis AG
  • Dormant Products, H2 2017

The ODAC reviewed findings from one Phase III clinical study and one Phase II study.

  • Cancer
  • Oncology
  • Ovarian Cancer
  • Therapy
  • Novartis AG

Patients are being randomized ##:## to VB-## in combination with chemotherapy, or chemotherapy alone.

  • Ovarian Cancer
  • Therapy
  • United States
  • Company Operations
  • Vascular Biogenics Ltd.
  • Clinical Trial profile. 41 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Ovarian Cancer
  • World
  • Product Initiative
  • PIPELINE BY CLOVIS ONCOLOGY INC, H2 2017
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H2 2017

PHIL., UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA DURING THE POSTER SESSION TITLED GASTROINTESTINAL (NON-COLORECTAL) CANCER".

  • Oncology
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC

Eighty-one percent (##/ ##) had = ## positive immunogenicity assay.

  • Diagnostic Reagent
  • Lymphoma
  • Ovarian Cancer
  • United States
  • Immunovaccine Inc.

Interest will be payable semi-annually in arrears on April ## and October ## of each year, beginning on April ##, 2015.

  • Chemotherapy
  • Ovarian Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Clinical Trial profile. 136 Trial Title
  • Official Title

## ## ## Merck & Co Inc ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Italian Sarcoma Group ## ## ##

  • Clinical Trial
  • Monoclonal Antibody
  • Ovarian Cancer
  • World
  • Product Initiative

The company' s product pipeline includes PI##K GDC-##; Cantrixil (TRX-E-##-##); Trilexium (TRXE-##-##).

  • Brain Cancer
  • Ovarian Cancer
  • Australia
  • United States
  • Novogen Limited
  • Clinical Trial profile. 369 Trial Title
  • Clinical Trial profile. 866 Trial Title

Peritoneal Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Peritoneal Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Peritoneal Cancer clinical trials scenario.This report provides top line data relating to the clinical trials on...

  • Cancer
  • Clinical Trial
  • Ovarian Cancer
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## ## ## ## ## Sanofi ## ## ## ## ## ## Regeneron Pharmaceuticals Inc ## ## ## ## ## ## MRC Biotech Pty Ltd (Inactive) ## ## ## ## ## ## Kazia Therapeutics Ltd ## ## ## ## ## ## HealthCare Global Enterprises Ltd ## ## ## ## ##

  • Ovarian Cancer
  • Therapy
  • World
  • Product Initiative
  • NeoPharm, Inc.

The company' s product pipeline includes PI##K GDC-##; Cantrixil (TRX-E-##-##); Trilexium (TRXE-##-##).

  • Brain Cancer
  • Ovarian Cancer
  • Australia
  • United States
  • Novogen Limited
  • PIPELINE BY CLOVIS ONCOLOGY INC, H1 2018
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H1 2018

GASTROINTESTINAL TEAES WERE IN LINE WITH HISTORIC IR-V DATA.

  • Oncology
  • Ovarian Cancer
  • Therapy
  • United States
  • AstraZeneca PLC
  • CLINICAL TRIAL PROFILE. 868 TRIAL TITLE
  • CLINICAL TRIAL PROFILE. 680 TRIAL TITLE

Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

  • Cancer
  • Chemotherapy
  • Clinical Trial
  • Ovarian Cancer
  • World
  • and hypoxia inducible factor 1alpha.

KCN-## acts by inhibiting hypoxia inducible factor ## alpha (HIF-## alpha) interaction.

  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cerulean
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H1 2018
  • PIPELINE BY JIANGSU HENGRUI MEDICINE CO LTD, H1 2018

GASTROINTESTINAL TEAES WERE IN LINE WITH HISTORIC IR-V DATA.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC

KCN-## acts by inhibiting hypoxia inducible factor ## alpha (HIF-## alpha) interaction.

  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cerulean

Such endoscopic data reflect the ability of Brilacidin to help clear Gastrointestinal (GI) tract mucosa in patients suffering from UC.

  • Ovarian Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Cellceutix Corporation

The main treatment-emergent adverse events have been low grade gastrointestinal and central nervous system related events.

  • Monoclonal Antibody
  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative

Interest is payable semi-annually on May ## and November ## of each year.

  • Ovarian Cancer
  • United States
  • Company
  • Supply
  • Clovis Oncology, Inc.

Grosu. ## to ## p. m.

  • Cancer
  • Ovarian Cancer
  • United States
  • Company
  • Novocure